Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program

Muller V, Banys-Paluchowski M, Friedl TWP, Fasching P, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, Huober J, Rübner M, Hoffmann O, Muller L, Janni W, Wimberger P, Jager B, Pantel K, Harbeck N, Fehm T (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Cancer Research American Association for Cancer Research

Publisher: AMER ASSOC CANCER RESEARCH

City/Town: PHILADELPHIA

Conference Proceedings Title: CANCER RESEARCH

DOI: 10.1158/1538-7445.SABCS20-PS2-02

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe Matthias Rübner Department of Obstetrics and Gynaecology

Involved external institutions

Universitätsklinikum Ulm

Germany (DE) Asklepios Klinik Altona

Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE)

Germany (DE) Universitätsklinikum Düsseldorf

Germany (DE) Technische Universität Dresden

Germany (DE) Universitätsklinikum Heidelberg

Germany (DE) Universitätsklinikum Essen

Germany (DE) Universitätsklinikum Tübingen

Germany (DE) Klinikum der Universität München

Germany (DE)

How to cite

APA:

Muller, V., Banys-Paluchowski, M., Friedl, T.W.P., Fasching, P., Schneeweiss, A., Hartkopf, A.,... Fehm, T. (2021). Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. Cancer Research. https://doi.org/10.1158/1538-7445.SABCS20-PS2-02

MLA:

Muller, Volkmar, et al. "Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program." Cancer Research (2021).

BibTeX: Download